Edwards Lifesciences Corporation filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 4, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Total assets of $14,144.4 million as of September 30, 2026, up from $13,697.2 million at December 31, 2025, according to the filing.
  • Cash and cash equivalents of $3,110.8 million at quarter-end, compared with $2,938.0 million at December 31, 2025.
  • Short-term investments of $1,533.9 million as of September 30, 2026, versus $1,288.3 million at year-end 2025.
  • Goodwill increased to $1,951.7 million from $1,768.6 million at December 31, 2025.
  • Total liabilities decreased to $3,182.9 million from $3,359.6 million at December 31, 2025.
  • 575.0 million shares of common stock outstanding as of October 31, 2026, as reported by the company.

Edwards Lifesciences Balance Sheet Positions at September 30, 2026

According to the filing, Edwards Lifesciences Corporation (NYSE:EW) reported total current assets of $7,247.5 million as of September 30, 2026, rising from $6,738.9 million at December 31, 2025. The company disclosed accounts receivable, net of allowances of $17.0 million, of $784.9 million, up from $659.6 million at year-end. Inventories stood at $1,159.4 million, compared with $1,126.2 million at the prior year-end.

On the liabilities side, the filing reported total current liabilities of $1,576.7 million as of September 30, 2026, a decrease from $1,813.7 million at December 31, 2025. Accrued and other liabilities declined to $1,352.1 million from $1,561.7 million. Long-term debt was reported at $598.8 million, essentially unchanged from $598.3 million at year-end 2025. Uncertain tax positions increased to $580.3 million from $502.7 million.

The company disclosed that goodwill rose to $1,951.7 million from $1,768.6 million, while other intangible assets, net, increased to $1,161.1 million from $1,128.2 million. Deferred income taxes declined to $929.4 million from $1,138.1 million. The filing also noted risks associated with, among other items, the sale of the company's Critical Care product group and the impact of tariffs or trade restrictions, as part of its forward-looking statements cautionary disclosures, which the company states are subject to substantial risks and uncertainties.

What Was Disclosed

Edwards Lifesciences filed its Form 10-Q for the quarter ended September 30, 2026, disclosing condensed consolidated balance sheet data showing total assets of $14,144.4 million, total liabilities of $3,182.9 million, and 575.0 million common shares outstanding as of October 31, 2026.